Compare MITK & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITK | ALLO |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.9M | 707.6M |
| IPO Year | 1995 | 2018 |
| Metric | MITK | ALLO |
|---|---|---|
| Price | $17.25 | $2.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $15.00 | $8.35 |
| AVG Volume (30 Days) | 993.9K | ★ 8.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.43 | 34.09 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $45,390,000.00 | N/A |
| Revenue This Year | $9.55 | N/A |
| Revenue Next Year | $8.07 | $142,416.42 |
| P/E Ratio | $69.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.53 | $0.99 |
| 52 Week High | $17.97 | $4.46 |
| Indicator | MITK | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 60.75 | 51.40 |
| Support Level | $13.15 | $1.85 |
| Resistance Level | $17.97 | $2.36 |
| Average True Range (ATR) | 0.88 | 0.13 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 80.29 | 70.59 |
Mitek Systems Inc is engaged in the development, sale, and service of proprietary software solutions related to mobile imaging. The firm is a software development company with expertise in artificial intelligence, and machine learning. It serves more than 7,900 financial services organizations, financial technology (fintech) brands, telecommunications companies, and marketplace brands across the globe. The company's Mobile Deposit solution is used by consumers for mobile check deposits. The company's Mobile Verify verifies a user's identity online, enabling organizations to build safer digital communities, whereas CheckReader enables financial institutions to automatically extract data from a check image received across any deposit channel - branch, ATM, RDC, and mobile.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).